
Pancreatic Cancer: Research-driven Clinical Progress Examined at AACR Special Conference
With a five-year survival rate of only 12.5%, any progress toward new therapeutic approaches for pancreatic cancer is welcomed...
With a five-year survival rate of only 12.5%, any progress toward new therapeutic approaches for pancreatic cancer is welcomed...
Our immune systems are equipped to recognize and destroy cancer cells—if they can find them, that is. And with...
Cancers are driven by unique genetic alterations, so what if we targeted these alterations to treat the cancer? It seems...
For our readers who enjoy learning about the newest tools and strategies in cancer research, the second installment of...
Neuroblastoma, a rare cancer that occurs primarily in children, is a scientific paradox, said pediatric oncologist John M. Maris,...
The AACR Annual Meeting 2023, held April 14-19, commemorated several milestones, including the 25th anniversary of the approval of...
As the temperatures start to drop and the leaves begin to change color, enjoy the latest selection of studies...
FDA approvals issued in third quarter 2023 included a new treatment for prostate cancer harboring BRCA mutations, two new...
Based on estimates from the National Cancer Institute, in 2023, more than 110,000 cases of gynecologic cancers are expected...
As you say farewell to summer, say hello to the latest installment of Editors’ Picks selected by the editors...